Article Trunk

Head And Neck Cancer Therapeutics Market Poised to Expand at a Robust Pace of USD 3.5 Billion Over 2030: Grand View Research Inc.

05.30.2023 · Posted in Business News Article

Head And Neck Cancer Therapeutics Market Growth & Trends 

The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm’s Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Request a free sample copy or view report summary: Head And Neck Cancer Therapeutics Market Report

Head And Neck Cancer Therapeutics Market Report Highlights 

  • By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases
  • By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
  • By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden
  • Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China

Access Press Release@

Head And Neck Cancer Therapeutics Market Segmentation

Grand View Research has segmented the global head and neck cancer therapeutics market on the basis of therapy type, route of administration, distribution channel, and region:

Head And Neck Cancer Therapy Type Outlook (Revenue, USD Million, 2018 – 2030)

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

Head And Neck Cancer Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 – 2030)

  • Injectable
  • Oral

Head And Neck Cancer Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018 – 2030)

  • Retail & Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Head And Neck Cancer Therapeutics Regional Outlook (Revenue, USD Million, 2018 – 2030)

  • North America
    • US.
    • Canada
  • Europe
    • UK.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

List of Key Players in the Head And Neck Cancer Therapeutics Market 

  • Eli Lilly and Company
  • Sanofi
  • Merck & Co., Inc.
  • Clinigen Group plc.
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Hoffmann-La Roche Ltd.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Comments are closed